
Janux Therapeutics Inc. (NASDAQ:JANX) stock hit a 52-week low on Tuesday after the company released updated interim data for its JANX007 Phase 1 program for metastatic castration-resistant prostate cancer (mCRPC).
As of October 15, 2025, data cutoff, 109 patients have been treated across the Phase 1a dose escalation and Phase 1b expansion trials of JANX007.